Where can I buy Alpelisib in the country?

Alpelisib (Alpelisib)-Piqray’s original drug has not yet received official marketing approval in China, so it cannot be purchased through regular pharmacies or hospitals in China. Domestic patients who want to obtain Apelvis can only rely on overseas channels or participate in clinical trials. Medical insurance coverage and price information are still unclear. In contrast, Apelvis is already on the market in Europe and the United States, and is mainly targeted at patients with advanced breast and ovarian cancer who are HR-positive, HER2-negative, and have PIK3CA mutations.

In overseas markets, the original drug Apelvis mainly has European and Indian versions. The European version has a specification of 150 mg At the same time, generic versions of drugs have been released in overseas markets. For example, the 150 mg × 28 tablets of generic drugs produced by Laos Pharmaceutical Factory have basically the same drug ingredients as the original drugs, providing patients with a more economical choice.

It should be noted that people who obtain Apelvis through overseas channels should strictly follow the guidance of doctors to determinePIK3CA mutation status, evaluate liver and kidney function and potential adverse reactions, and avoid blind use. Apelvis is often used in combination with endocrine therapy drugs. Used alone, it has limited efficacy and may cause side effects such as hyperglycemia, rash, and gastrointestinal discomfort. Patients need to regularly monitor blood sugar, liver function and skin conditions during use, and adjust the dosage or combination plan according to the doctor's recommendations.

In general, Apelvis is not yet on the market in China, but overseas original drugs and generic drugs provide feasible ways for Chinese patients to obtain it. With the advancement of clinical research and registration approval in the future, Apelvis is expected to enter the Chinese market, providing a new option for targeted therapy for patients with HR-positive and HER2-negative breast cancer, and may also promote domestic price rationalization and medical insurance coverage.

Reference materials:https://www.piqray.com/